Wave life sciences to highlight leading rna editing capability and multimodal discovery and development platform at asgct 26th annual meeting

Presentations include new data showing wve-006 improved markers of liver disease in mice; wve-006 is a first-in-class rna editing therapeutic for alpha-1 antitrypsin deficiency (aatd) which is designed to restore healthy, wild-type aat protein
WVE Ratings Summary
WVE Quant Ranking